Evidence in Favor of Braak Staging of Parkinson's Disease

被引:102
|
作者
Dickson, Dennis W. [1 ]
Uchikado, Hirotake
Fujishiro, Hiroshige
Tsuboi, Yoshio
机构
[1] Mayo Clin, Neuropathol Lab, Dept Neurosci, Jacksonville, FL 32224 USA
关键词
alpha-synuclein; Lewy bodies; Parkinson's disease staging; neuropathology; ALPHA-SYNUCLEIN PATHOLOGY; AUTONOMIC NERVOUS-SYSTEM; LEWY BODY DISEASE; ALZHEIMERS-DISEASE; BRAIN PATHOLOGY; BODIES; DEMENTIA; INCLUSIONS; DIAGNOSIS; AMYGDALA;
D O I
10.1002/mds.22637
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recently, Braak and coworkers proposed a pathologic staging scheme for Parkinson disease (PD). In this staging, scheme substantia nigra pathology occurs at midstage disease, while involvement of anterior olfactory nucleus, medulla, and pontine tegmentum occur earlier. In the last stages. Lewy bodies (LBs) involve cortical areas. The general principles of the proposed staging system have been confirmed in several studies of PD, but it does not appear to fit with all LB disorders. We studied the density and distribution of LBs with alpha-synuclein immunohistochemistry in normal elderly with incidental LBs (N = 12); progressive supranuclear palsy (PSP) with incidental LBs (N = 18); Lewy body disease (LBD) with minimal or no Alzheimer type pathology (N = 52); LBD with concomitant Alzheimer disease (AD) (N 84); and cases of AD with amygdala predominant LBs (N = 64). The proportion of cases that fit the PD staging scheme was 67% for incidental LBs; 86% for PSP with LBs; 86% for pure LBD; and 84% for LBD with AD; but only 6% for AD with amygdala predominant LBs. The PD staging scheme is valid, except in the setting of advanced AD. In this situation, LBs may be unrelated to PD and more likely related to factors inherent to AD and the selective vulnerability of the amygdala to both Alzheimer and alpha-synuclein pathologies. (C) 2010 Movement Disorder Society
引用
收藏
页码:S78 / S82
页数:5
相关论文
共 50 条
  • [21] Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease
    Eva Gschmack
    Camelia-Maria Monoranu
    Hecham Marouf
    Sarah Meyer
    Lena Lessel
    Raja Idris
    Daniela Berg
    Walter Maetzler
    Frank Steigerwald
    Jens Volkmann
    Manfred Gerlach
    Peter Riederer
    Eleni Koutsilieri
    Carsten Scheller
    [J]. Journal of Neural Transmission, 2022, 129 : 545 - 555
  • [22] Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease
    Gschmack, Eva
    Monoranu, Camelia-Maria
    Marouf, Hecham
    Meyer, Sarah
    Lessel, Lena
    Idris, Raja
    Berg, Daniela
    Maetzler, Walter
    Steigerwald, Frank
    Volkmann, Jens
    Gerlach, Manfred
    Riederer, Peter
    Koutsilieri, Eleni
    Scheller, Carsten
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (5-6) : 545 - 555
  • [23] Non-motor symptoms in Parkinson's disease and the model of Braak
    You, H.
    Lejeune, F. X.
    Danjou, F.
    Bekadar, S.
    Corvol, J. C.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S360 - S360
  • [24] Evidence against a reliable staging system of α-synuclein pathology in Parkinson's disease
    Kalaitzakis, M. E.
    Graeber, M. B.
    Gentleman, S. M.
    Pearce, R. K. B.
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2009, 35 (01) : 125 - 126
  • [25] Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer’s Disease
    A. C. Macedo
    D. F. P. A. Durço
    C. Tissot
    J. Therriault
    A. O. Vilela de Faria
    É. Aumont
    S. Servaes
    N. Rahmouni
    J. Fernandez-Arias
    Y.-T. Wang
    F. Z. Lussier
    A. Bieger
    E. R. Zimmer
    T. A. Pascoal
    S. Gauthier
    Pedro Rosa-Neto
    [J]. The Journal of Prevention of Alzheimer's Disease, 2024, 11 : 414 - 421
  • [26] Biomarker modeling of Alzheimer's disease using PET-based Braak staging
    Therriault, Joseph
    Pascoal, Tharick A.
    Lussier, Firoza Z.
    Tissot, Cecile
    Chamoun, Mira
    Bezgin, Gleb
    Servaes, Stijn
    Benedet, Andrea L.
    Ashton, Nicholas J.
    Karikari, Thomas K.
    Lantero-Rodriguez, Juan
    Kunach, Peter
    Wang, Yi-Ting
    Fernandez-Arias, Jaime
    Massarweh, Gassan
    Vitali, Paolo
    Soucy, Jean-Paul
    Saha-Chaudhuri, Paramita
    Blennow, Kaj
    Zetterberg, Henrik
    Gauthier, Serge
    Rosa-Neto, Pedro
    [J]. NATURE AGING, 2022, 2 (06): : 526 - +
  • [27] Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
    Joseph Therriault
    Tharick A. Pascoal
    Firoza Z. Lussier
    Cécile Tissot
    Mira Chamoun
    Gleb Bezgin
    Stijn Servaes
    Andrea L. Benedet
    Nicholas J. Ashton
    Thomas K. Karikari
    Juan Lantero-Rodriguez
    Peter Kunach
    Yi-Ting Wang
    Jaime Fernandez-Arias
    Gassan Massarweh
    Paolo Vitali
    Jean-Paul Soucy
    Paramita Saha-Chaudhuri
    Kaj Blennow
    Henrik Zetterberg
    Serge Gauthier
    Pedro Rosa-Neto
    [J]. Nature Aging, 2022, 2 : 526 - 535
  • [28] Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease
    Macedo, A. C.
    Durco, D. F. P. A.
    Tissot, C.
    Therriault, J.
    de Faria, A. O. Vilela
    Aumont, E.
    Servaes, S.
    Rahmouni, N.
    Fernandez-Arias, J.
    Wang, Y. -t.
    Lussier, F. Z.
    Bieger, A.
    Zimmer, E. R.
    Pascoal, T. A.
    Gauthier, S.
    Rosa-Neto, Pedro
    [J]. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2024, 11 (02): : 414 - 421
  • [29] Braak model in Parkinson disease using MRI biomarkers
    Pyatigorskaya, N.
    Yahia-Cherif, L.
    Valabregue, R.
    Gaurav, R.
    Mongin, M.
    Ewenczyk, C.
    Gallea, C.
    Gargouri, F.
    Bardinet, E.
    Arnulf, I.
    Vidailhet, M.
    Lehericy, S.
    [J]. MOVEMENT DISORDERS, 2019, 34
  • [30] Frontostriatal Cognitive Staging in Parkinson's Disease
    de la Fuente-Fernandez, Raul
    [J]. PARKINSONS DISEASE, 2012, 2012